首页 > 最新文献

Obstetrics and Gynecology Science最新文献

英文 中文
Development of an endometriosis self-assessment tool for patient. 为患者开发子宫内膜异位症自我评估工具。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-29 DOI: 10.5468/ogs.21252.e1
Hyun-Hee Cho, Young-Sub Yoon
{"title":"Development of an endometriosis self-assessment tool for patient.","authors":"Hyun-Hee Cho, Young-Sub Yoon","doi":"10.5468/ogs.21252.e1","DOIUrl":"10.5468/ogs.21252.e1","url":null,"abstract":"","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"431-432"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of oxidative stress and inflammation in patients with polycystic ovary syndrome. 评估多囊卵巢综合征患者的氧化应激和炎症。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-17 DOI: 10.5468/ogs.24031
Berra Sen, Senem Gonultas, Ceren Albayrak, Sevval Temur, Ilgar Acar, Beyza Nur Ozkan, Havva Sevde Islek, Muserref Banu Yilmaz, Ebru Kale, Eray Metin Guler

Objective: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine and metabolic disorder characterized by hyperandrogenism, hyperinsulinemia, and insulin resistance. The prevalence of PCOS is increasing worldwide. Although the etiology of this disease is currently unknown, it is thought to be closely related to inflammation and oxidative stress. Our study aimed to compare patients have PCOS to healthy volunteers and assess the changes in oxidative stress and inflammatory parameters in these patients.

Methods: Thirty patients between the ages of 18-45 diagnosed with PCOS and 30 healthy volunteers with the same demographic characteristics were included in this study. Clinical parameters were measured using immunoassays. Oxidative stress biomarkers, total oxidant (TOS), total antioxidant (TAS), total thiol (TT), and native thiol (NT) levels were measured using photometric methods according to Erel's method. The dynamic disulfide level (DIS) and oxidative stress index (OSI) were calculated using mathematical equations. Among the inflammatory parameters, values for interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) were measured photometrically using commercially purchased kits.

Results: Moreover, TT and NT levels were lower in patients with PCOS compared to those in the healthy group statistically significantly (P<0.001). In addition, TAS, TOS, OSI, DIS, IL-1β, IL-6, and TNF-α levels were identified to be significantly higher in the patients with PCOS than those in the healthy group (P<0.001).

Conclusion: Evaluation of oxidative stress and clinical parameters used in the follow-up may be beneficial for the disease.

目的:多囊卵巢综合征(PCOS)是一种以高雄激素、高胰岛素血症和胰岛素抵抗为特征的异质性内分泌和代谢疾病。多囊卵巢综合征的发病率在全球范围内呈上升趋势。虽然该病的病因目前尚不清楚,但被认为与炎症和氧化应激密切相关。我们的研究旨在将多囊卵巢综合征患者与健康志愿者进行比较,并评估这些患者体内氧化应激和炎症指标的变化:方法:本研究纳入了 30 名年龄在 18-45 岁之间的多囊卵巢综合征患者和 30 名具有相同人口统计学特征的健康志愿者。采用免疫测定法测量临床参数。氧化应激生物标志物、总氧化剂(TOS)、总抗氧化剂(TAS)、总硫醇(TT)和原生硫醇(NT)的水平是根据 Erel 的方法用光度法测量的。动态二硫化物水平(DIS)和氧化应激指数(OSI)通过数学公式计算得出。在炎症参数中,白细胞介素(IL)-1β、IL-6 和肿瘤坏死因子-α(TNF-α)的值是用市售试剂盒通过光度法测量的:此外,与健康组相比,多囊卵巢综合征患者的TT和NT水平明显降低(PC结论:评估氧化应激和用于随访的临床参数可能对疾病有益。
{"title":"Evaluation of oxidative stress and inflammation in patients with polycystic ovary syndrome.","authors":"Berra Sen, Senem Gonultas, Ceren Albayrak, Sevval Temur, Ilgar Acar, Beyza Nur Ozkan, Havva Sevde Islek, Muserref Banu Yilmaz, Ebru Kale, Eray Metin Guler","doi":"10.5468/ogs.24031","DOIUrl":"10.5468/ogs.24031","url":null,"abstract":"<p><strong>Objective: </strong>Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine and metabolic disorder characterized by hyperandrogenism, hyperinsulinemia, and insulin resistance. The prevalence of PCOS is increasing worldwide. Although the etiology of this disease is currently unknown, it is thought to be closely related to inflammation and oxidative stress. Our study aimed to compare patients have PCOS to healthy volunteers and assess the changes in oxidative stress and inflammatory parameters in these patients.</p><p><strong>Methods: </strong>Thirty patients between the ages of 18-45 diagnosed with PCOS and 30 healthy volunteers with the same demographic characteristics were included in this study. Clinical parameters were measured using immunoassays. Oxidative stress biomarkers, total oxidant (TOS), total antioxidant (TAS), total thiol (TT), and native thiol (NT) levels were measured using photometric methods according to Erel's method. The dynamic disulfide level (DIS) and oxidative stress index (OSI) were calculated using mathematical equations. Among the inflammatory parameters, values for interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) were measured photometrically using commercially purchased kits.</p><p><strong>Results: </strong>Moreover, TT and NT levels were lower in patients with PCOS compared to those in the healthy group statistically significantly (P<0.001). In addition, TAS, TOS, OSI, DIS, IL-1β, IL-6, and TNF-α levels were identified to be significantly higher in the patients with PCOS than those in the healthy group (P<0.001).</p><p><strong>Conclusion: </strong>Evaluation of oxidative stress and clinical parameters used in the follow-up may be beneficial for the disease.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"414-420"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydroxychloroquine in obstetrics: potential implications of the prophylactic use of hydroxychloroquine for placental insufficiency during pregnancy. 产科中的羟氯喹:预防性使用羟氯喹治疗妊娠期胎盘功能不全的潜在影响。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-28 DOI: 10.5468/ogs.23252.e1
Yoo-Min Kim, Ji-Hee Sung, Hyun-Hwa Cha, Soo-Young Oh
{"title":"Hydroxychloroquine in obstetrics: potential implications of the prophylactic use of hydroxychloroquine for placental insufficiency during pregnancy.","authors":"Yoo-Min Kim, Ji-Hee Sung, Hyun-Hwa Cha, Soo-Young Oh","doi":"10.5468/ogs.23252.e1","DOIUrl":"10.5468/ogs.23252.e1","url":null,"abstract":"","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"433"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141066159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women. 韩国绝经后妇女接受屈螺酮 2 毫克/17β-雌二醇 1 毫克激素疗法的有效性和安全性。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-28 DOI: 10.5468/ogs.2017.60.2.213.e1
Bo Ra Park, Hye Na Park, Ji Back Jung, Eun Sil Lee, Jeong Sig Kim, Gyu Yeon Choi, Jeong Jae Lee, Im Soon Lee
{"title":"Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women.","authors":"Bo Ra Park, Hye Na Park, Ji Back Jung, Eun Sil Lee, Jeong Sig Kim, Gyu Yeon Choi, Jeong Jae Lee, Im Soon Lee","doi":"10.5468/ogs.2017.60.2.213.e1","DOIUrl":"10.5468/ogs.2017.60.2.213.e1","url":null,"abstract":"","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"430"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chitinase-3-like protein 1, matrix metalloproteinase-9, and monocyte chemoattractant protein-1 as potential biomarkers and treatment targets of adenomyosis. 几丁质酶-3样蛋白1、基质金属蛋白酶-9和单核细胞趋化蛋白-1是子宫腺肌病的潜在生物标记物和治疗靶标。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-06-11 DOI: 10.5468/ogs.24021
Alvin Setiawan, Hanom Husni Syam, Wiryawan Permadi, Ruswana Anwar, Tita Husnitawati Madjid, Dian Tjahyadi, Putu Doster Mahayasa

Objective: This study aimed to investigate the levels of chitinase-3-like protein-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9), and monocyte chemoattractant protein-1 (MCP-1) in adenomyosis, as compared to normal myometrial tissue. These biomarkers may be useful for determining potential treatment targets.

Methods: This was a correlative, analytical, and observational study with a cross-sectional design. Participants with a diagnosis of moderate-to-severe adenomyosis, as determined through transvaginal ultrasonography and histological examination, and who underwent laparotomy or laparoscopic surgery for the treatment of adenomyosis, were enrolled in the study. Unlike other studies that recruited healthy women as controls, our study used adenomyotic and healthy nonadenomyotic myometria obtained from the same individual. The levels of CHI3L1, MMP-9, and MCP-1 in the biopsy samples were determined using enzyme-linked immunoassay kits, according to the manufacturer's protocol.

Results: A highly significant increase in the levels of CHI3L1, MMP-9, and MCP-1 was found in adenomyotic tissues compared to non-adenomyotic tissues (P<0.001). A significant positive correlation was found between CHI3L1 and MMP-9 levels (r=0.463; P=0.008), CHI3L1 and MCP-1 levels (r=0.594; P<0.001), and MCP-1 and MMP-9 levels (r=0.680; P<0.001) in adenomyotic tissues.

Conclusion: CHI3L1 may play a role in the pathogenesis of adenomyosis via the regulation of the MCP-1 and MMP-9 pathways. Therefore, these molecules may serve as biomarkers and potential therapeutic targets for adenomyosis.

研究目的本研究旨在探讨与正常子宫肌腺症组织相比,子宫腺肌症患者体内甲壳素酶-3样蛋白-1(CHI3L1)、基质金属蛋白酶-9(MMP-9)和单核细胞趋化蛋白-1(MCP-1)的水平。这些生物标志物可能有助于确定潜在的治疗目标:这是一项横断面设计的相关性、分析性和观察性研究。通过经阴道超声波检查和组织学检查确诊患有中度至重度子宫腺肌症,并接受开腹手术或腹腔镜手术治疗子宫腺肌症的患者被纳入研究。与其他招募健康妇女作为对照的研究不同,我们的研究使用了从同一个人身上获得的腺肌症和健康的非腺肌症子宫肌层。活检样本中的 CHI3L1、MMP-9 和 MCP-1 含量是根据制造商提供的酶联免疫测定试剂盒测定的:结果:与非腺肌症组织相比,腺肌症组织中CHI3L1、MMP-9和MCP-1的水平有非常明显的升高(PC结论:CHI3L1可能在腺肌症组织中发挥重要作用:CHI3L1可能通过调节MCP-1和MMP-9途径在子宫腺肌症的发病机制中发挥作用。因此,这些分子可作为子宫腺肌病的生物标记物和潜在治疗靶点。
{"title":"Chitinase-3-like protein 1, matrix metalloproteinase-9, and monocyte chemoattractant protein-1 as potential biomarkers and treatment targets of adenomyosis.","authors":"Alvin Setiawan, Hanom Husni Syam, Wiryawan Permadi, Ruswana Anwar, Tita Husnitawati Madjid, Dian Tjahyadi, Putu Doster Mahayasa","doi":"10.5468/ogs.24021","DOIUrl":"10.5468/ogs.24021","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the levels of chitinase-3-like protein-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9), and monocyte chemoattractant protein-1 (MCP-1) in adenomyosis, as compared to normal myometrial tissue. These biomarkers may be useful for determining potential treatment targets.</p><p><strong>Methods: </strong>This was a correlative, analytical, and observational study with a cross-sectional design. Participants with a diagnosis of moderate-to-severe adenomyosis, as determined through transvaginal ultrasonography and histological examination, and who underwent laparotomy or laparoscopic surgery for the treatment of adenomyosis, were enrolled in the study. Unlike other studies that recruited healthy women as controls, our study used adenomyotic and healthy nonadenomyotic myometria obtained from the same individual. The levels of CHI3L1, MMP-9, and MCP-1 in the biopsy samples were determined using enzyme-linked immunoassay kits, according to the manufacturer's protocol.</p><p><strong>Results: </strong>A highly significant increase in the levels of CHI3L1, MMP-9, and MCP-1 was found in adenomyotic tissues compared to non-adenomyotic tissues (P<0.001). A significant positive correlation was found between CHI3L1 and MMP-9 levels (r=0.463; P=0.008), CHI3L1 and MCP-1 levels (r=0.594; P<0.001), and MCP-1 and MMP-9 levels (r=0.680; P<0.001) in adenomyotic tissues.</p><p><strong>Conclusion: </strong>CHI3L1 may play a role in the pathogenesis of adenomyosis via the regulation of the MCP-1 and MMP-9 pathways. Therefore, these molecules may serve as biomarkers and potential therapeutic targets for adenomyosis.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"421-429"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Living lab modelling as a pilot study assessing the potential psychological health benefits of forest environment for cancer survivors. 将生活实验室模型作为一项试点研究,评估森林环境对癌症幸存者心理健康的潜在益处。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-06-12 DOI: 10.5468/ogs.24035
Mi-Kyung Kim, Hyo Jin Park, Kyung Ju Lee

Objective: To evaluate the physiological and psychological changes in cancer survivors who engage in repeated forest therapy in a living environment.

Methods: This study included stay-based forest therapy for female cancer survivors aged ≥40 years. The program was conducted in two cycles, each spanning 3 weeks and consisting of a 2-night, 3-day stay, followed by daily life integration. The cycles were repeated from July 2, 2022, to August 18, 2022. Participant assessment included standard physical health parameters and a questionnaire on general characteristics, lifestyle habits, stress levels, and health status.

Results: Thirty-seven female cancer survivors participated in the forest healing program, 56.8% of whom had a history of breast cancer. The median body mass index (BMI) was 23.80 kg/m2 (range, 21.00-25.60). More than half of the patients reported mild-to-moderate fatigue, chronic pain, and mild-to-moderate depression (81%, 65%, and 73%, respectively). After two cycles of forest therapy, no significant differences were observed in terms of fatigue, pain, or BMI levels. However, significant improvements were found in quality of life measures, particularly the psychological quality of life (mean score 12.54 at baseline vs. 13.48 after cycle 2; P=0.007). Positive improvements were also observed in terms of stress (mean score 17.03 vs. 13.76; P=0.002) and depression (mean score 8.35 vs. 6.11; P=0.002) levels.

Conclusion: Our forest-healing program demonstrated that nature-based therapies improve the mental health and quality of life of female cancer survivors, suggesting the need for further research on nature-based interventions to better support cancer survivors.

目的:评估在生活环境中反复进行森林疗法的癌症幸存者的生理和心理变化:评估在生活环境中反复进行森林疗法的癌症幸存者的生理和心理变化:本研究为年龄≥40 岁的女性癌症幸存者提供了基于住宿的森林疗法。该项目分两个周期进行,每个周期为期 3 周,包括 2 夜 3 天的住宿,以及随后的日常生活整合。从 2022 年 7 月 2 日到 2022 年 8 月 18 日重复进行。对参与者的评估包括标准身体健康参数以及关于一般特征、生活习惯、压力水平和健康状况的调查问卷:37名女性癌症幸存者参加了森林疗养计划,其中56.8%曾患乳腺癌。体重指数(BMI)中位数为 23.80 kg/m2(范围为 21.00-25.60)。半数以上的患者报告有轻度至中度疲劳、慢性疼痛和轻度至中度抑郁(分别为 81%、65% 和 73%)。经过两个周期的森林疗法后,在疲劳、疼痛或体重指数水平方面没有观察到显著差异。不过,在生活质量方面,尤其是心理生活质量方面,发现有明显改善(基线时的平均得分为 12.54,第二周期后为 13.48;P=0.007)。在压力(平均分 17.03 vs. 13.76;P=0.002)和抑郁(平均分 8.35 vs. 6.11;P=0.002)水平方面也观察到了积极的改善:我们的森林疗养计划表明,以自然为基础的疗法可以改善女性癌症幸存者的心理健康和生活质量,这表明有必要进一步研究以自然为基础的干预措施,为癌症幸存者提供更好的支持。
{"title":"Living lab modelling as a pilot study assessing the potential psychological health benefits of forest environment for cancer survivors.","authors":"Mi-Kyung Kim, Hyo Jin Park, Kyung Ju Lee","doi":"10.5468/ogs.24035","DOIUrl":"10.5468/ogs.24035","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the physiological and psychological changes in cancer survivors who engage in repeated forest therapy in a living environment.</p><p><strong>Methods: </strong>This study included stay-based forest therapy for female cancer survivors aged ≥40 years. The program was conducted in two cycles, each spanning 3 weeks and consisting of a 2-night, 3-day stay, followed by daily life integration. The cycles were repeated from July 2, 2022, to August 18, 2022. Participant assessment included standard physical health parameters and a questionnaire on general characteristics, lifestyle habits, stress levels, and health status.</p><p><strong>Results: </strong>Thirty-seven female cancer survivors participated in the forest healing program, 56.8% of whom had a history of breast cancer. The median body mass index (BMI) was 23.80 kg/m2 (range, 21.00-25.60). More than half of the patients reported mild-to-moderate fatigue, chronic pain, and mild-to-moderate depression (81%, 65%, and 73%, respectively). After two cycles of forest therapy, no significant differences were observed in terms of fatigue, pain, or BMI levels. However, significant improvements were found in quality of life measures, particularly the psychological quality of life (mean score 12.54 at baseline vs. 13.48 after cycle 2; P=0.007). Positive improvements were also observed in terms of stress (mean score 17.03 vs. 13.76; P=0.002) and depression (mean score 8.35 vs. 6.11; P=0.002) levels.</p><p><strong>Conclusion: </strong>Our forest-healing program demonstrated that nature-based therapies improve the mental health and quality of life of female cancer survivors, suggesting the need for further research on nature-based interventions to better support cancer survivors.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"404-413"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The influence of advanced maternal age on congenital malformations, short- and long-term outcomes in offspring of nulligravida: a Korean National Cohort Study over 15 years. 高龄产妇对无效妊娠后代先天性畸形、短期和长期预后的影响:一项历时 15 年的韩国全国队列研究。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-04-26 DOI: 10.5468/ogs.24005
Su Jin You, Danbee Kang, Ji-Hee Sung, Hyejeong Park, Juhee Cho, Suk-Joo Choi, Soo-Young Oh, Cheong-Rae Roh

Objective: To assess the influence of advanced maternal age on congenital malformations, short- and long-term outcomes in offspring of nulligravida.

Methods: A retrospective study was conducted using the Korean National Health Insurance Service database spanning from January 2005 to December 2019. All live-born offspring of nulligravida (n=3,685,817) were included. The maternal age was subdivided into the following subgroups: <25 years (n=153,818), 25-29 years (n=845,355), 30-34 years (n=1,738,299), 35-39 years (n=787,530), 40-44 years (n=151,519), and >44 years (n=9,296). Outcomes were assessed based on International Classification of Diseases-10 codes. Adjusted odds ratios (aOR) were calculated with the group of 25-29 years as a reference.

Result: Most congenital malformations showed an age dependent increase, but cleft lip and abdominal wall defect exhibited a U-shape curve, indicating an increase even in those <25 years old. Similarly, various disorders included in the neonatal composite outcomes from short-term outcomes showed aged dependent escalation. However, the preterm birth from the short-term outcome and most of the long-term developmental outcomes, except for motor developmental delay and Tics, showed a U-shaped pattern. The aOR of autism and cerebral palsy, showing the most obvious U-shaped curved in the long-term outcomes, was 1.50 (95% confidence interval [CI], 1.24-1.82) and 1.54 (95% CI, 1.17-2.03), respectively in the group >44 years old and 1.18 (95% CI, 1.11-1.25) and 1.19 (95% CI, 1.09-1.30) in <25 years old group.

Conclusion: Overall, an advanced maternal age has an age-dependent correlation with most congenital malformations and shortand long-term outcomes of neonates.

目的评估高龄产妇对空怀孕产妇后代先天性畸形以及短期和长期预后的影响:利用韩国国民健康保险服务数据库(2005 年 1 月至 2019 年 12 月)进行了一项回顾性研究。纳入了所有无效妊娠的活产后代(n=3,685,817)。产妇年龄细分为以下亚组:44 岁(n=9,296)。结果根据 ICD-10 编码进行评估。使用逻辑回归和考克斯比例危险模型分析,以 25-29 岁组为参照,计算调整后的几率比(aORs):大多数先天性畸形的发病率随年龄增长,但唇裂和腹壁缺损的发病率呈 U 型曲线,表明 44 岁年龄组的发病率也有所上升,结论为 1.18(95% 置信区间[CI],1.11-1.25)和 1.19(95% 置信区间,1.09-1.30):总体而言,高龄产妇与大多数先天性畸形以及新生儿的短期和长期预后都有相关性。
{"title":"The influence of advanced maternal age on congenital malformations, short- and long-term outcomes in offspring of nulligravida: a Korean National Cohort Study over 15 years.","authors":"Su Jin You, Danbee Kang, Ji-Hee Sung, Hyejeong Park, Juhee Cho, Suk-Joo Choi, Soo-Young Oh, Cheong-Rae Roh","doi":"10.5468/ogs.24005","DOIUrl":"10.5468/ogs.24005","url":null,"abstract":"<p><strong>Objective: </strong>To assess the influence of advanced maternal age on congenital malformations, short- and long-term outcomes in offspring of nulligravida.</p><p><strong>Methods: </strong>A retrospective study was conducted using the Korean National Health Insurance Service database spanning from January 2005 to December 2019. All live-born offspring of nulligravida (n=3,685,817) were included. The maternal age was subdivided into the following subgroups: <25 years (n=153,818), 25-29 years (n=845,355), 30-34 years (n=1,738,299), 35-39 years (n=787,530), 40-44 years (n=151,519), and >44 years (n=9,296). Outcomes were assessed based on International Classification of Diseases-10 codes. Adjusted odds ratios (aOR) were calculated with the group of 25-29 years as a reference.</p><p><strong>Result: </strong>Most congenital malformations showed an age dependent increase, but cleft lip and abdominal wall defect exhibited a U-shape curve, indicating an increase even in those <25 years old. Similarly, various disorders included in the neonatal composite outcomes from short-term outcomes showed aged dependent escalation. However, the preterm birth from the short-term outcome and most of the long-term developmental outcomes, except for motor developmental delay and Tics, showed a U-shaped pattern. The aOR of autism and cerebral palsy, showing the most obvious U-shaped curved in the long-term outcomes, was 1.50 (95% confidence interval [CI], 1.24-1.82) and 1.54 (95% CI, 1.17-2.03), respectively in the group >44 years old and 1.18 (95% CI, 1.11-1.25) and 1.19 (95% CI, 1.09-1.30) in <25 years old group.</p><p><strong>Conclusion: </strong>Overall, an advanced maternal age has an age-dependent correlation with most congenital malformations and shortand long-term outcomes of neonates.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"380-392"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Basic knowledge for counseling patients undergoing risk-reducing salpingo-oophorectomy. 为接受降低风险的输卵管切除术的患者提供咨询的基本知识。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-31 DOI: 10.5468/ogs.24054
Jihye Kim, Chel Hun Choi

Significant progress has been made in the molecular diagnosis of cancer. It provides personalized medicine, including cancer diagnosis, prognosis, targeted therapy, and risk detection. These advances allow physicians to identify patients at risk for cancer before it develops and offer them an opportunity to prevent its development. Mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and 2) are one of the most well-known cancer-related gene mutations since actor Angelina Jolie shared her experience with genetic mutations and risk-reducing surgery in the media. In Korea, tests for germline BRCA1/2 mutations have been covered by insurance since May 2012 and the number of women of BRCA1/2 mutations has continued to increase over the past decade. Most carriers of BRCA1/2 mutations consider risk-reducing salpingo-oophorectomy (RRSO) resulting in early menopause and want to know the lifetime risks and benefits of RRSO. However, despite the increasing number of carriers of BRCA1/2 mutations, the counseling and management of patients requiring RRSO varies among physicians. This article provides basic knowledge on RRSO to help physicians comprehensively assess its risks and benefits and manage at-risk women.

癌症分子诊断已取得重大进展。它提供了个性化医疗,包括癌症诊断、预后、靶向治疗和风险检测。这些进步使医生能够在癌症发生之前识别出有患癌风险的病人,并为他们提供预防癌症发生的机会。自从演员安吉丽娜-朱莉(Angelina Jolie)在媒体上分享了她的基因突变和降低风险手术的经历后,乳腺癌易感基因 1 和 2(BRCA1 和 2)的突变成为最知名的癌症相关基因突变之一。在韩国,自 2012 年 5 月起,BRCA1/2 基因突变的检测已被纳入保险范围,BRCA1/2 基因突变携带者的人数在过去十年中持续增加。大多数 BRCA1/2 基因突变携带者都会考虑进行降低风险的输卵管切除术(RRSO),从而导致提早绝经,并希望了解 RRSO 的终生风险和益处。然而,尽管 BRCA1/2 基因突变携带者的人数不断增加,但不同医生对需要 RRSO 的患者的咨询和管理却各不相同。本文将提供有关 RRSO 的基本知识,帮助医生全面评估其风险和益处,并对高危女性进行管理。
{"title":"Basic knowledge for counseling patients undergoing risk-reducing salpingo-oophorectomy.","authors":"Jihye Kim, Chel Hun Choi","doi":"10.5468/ogs.24054","DOIUrl":"10.5468/ogs.24054","url":null,"abstract":"<p><p>Significant progress has been made in the molecular diagnosis of cancer. It provides personalized medicine, including cancer diagnosis, prognosis, targeted therapy, and risk detection. These advances allow physicians to identify patients at risk for cancer before it develops and offer them an opportunity to prevent its development. Mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and 2) are one of the most well-known cancer-related gene mutations since actor Angelina Jolie shared her experience with genetic mutations and risk-reducing surgery in the media. In Korea, tests for germline BRCA1/2 mutations have been covered by insurance since May 2012 and the number of women of BRCA1/2 mutations has continued to increase over the past decade. Most carriers of BRCA1/2 mutations consider risk-reducing salpingo-oophorectomy (RRSO) resulting in early menopause and want to know the lifetime risks and benefits of RRSO. However, despite the increasing number of carriers of BRCA1/2 mutations, the counseling and management of patients requiring RRSO varies among physicians. This article provides basic knowledge on RRSO to help physicians comprehensively assess its risks and benefits and manage at-risk women.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"343-355"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysis. 不同年龄患者非整倍体植入前基因检测:系统综述和荟萃分析。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-28 DOI: 10.5468/ogs.24028
Leila Adamyan, Laura Pivazyan, Lilia Obosyan, Ekaterina Krylova, Sapiyat Isaeva

This study aimed to summarize the current knowledge on the benefits of in vitro fertilization/intracytoplasmic sperm injection with preimplantation genetic testing for aneuploidy (PGT-A) and to discuss the role of PGT-A in patients of different ages undergoing assisted reproduction. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 checklist. Registration number: CRD42022354697. Studies were identified by searching the PubMed, Cochrane Library, Google Scholar, Scopus, Embase, and ClinicalTrials databases. Seven meta-analyses were performed with additional stratification of age and prognosis of the women studied. Clinical pregnancy rate per embryo transfer in patients aged >35 years was higher in the PGT-A group (P=0.0002) than in controls. Live birth rate (LBR) per embryo transfer in women 35 years old or younger (P=0.002) was higher in the PGT-A group. The LBR per patient in women aged >35 years was higher in the PGT-A group (P=0.004). The effects of PGT-A on LBR in patients with poor prognosis showed a statistically significant increase (P=0.003). There was no significant difference in the rate between the two groups. PGT-A is effective and can be recommended for patients aged >35 years undergoing assisted reproduction to improve their reproductive outcomes. Moreover, our study showed the possible benefits of PGT-A in patients with a poor prognosis. Overall, our findings suggest that PGT-A is a valuable tool for improving the reproductive outcomes of assisted reproductive procedures in older women and those with a history of pregnancy complications.

本研究旨在总结目前关于体外受精/卵胞浆内单精子注射联合植入前非整倍体基因检测(PGT-A)的益处的知识,并讨论 PGT-A 在接受辅助生殖的不同年龄患者中的作用。根据《2020 年系统综述和元分析首选报告项目》清单进行了系统综述。注册编号CRD42022354697。通过检索 PubMed、Cochrane Library、Google Scholar、Scopus、Embase 和 ClinicalTrials 数据库,确定了相关研究。进行了七项荟萃分析,并对研究对象的年龄和预后进行了分层。PGT-A 组年龄大于 35 岁的患者每次胚胎移植的临床妊娠率(P=0.0002)高于对照组。PGT-A 组中,35 岁或以下妇女每次胚胎移植的活产率(P=0.002)更高。在 PGT-A 组中,年龄大于 35 岁的妇女每次胚胎移植的活产率较高(P=0.004)。PGT-A 对预后不良患者 LBR 的影响有统计学意义的增加(P=0.003)。两组之间的比率无明显差异。PGT-A 效果显著,可推荐用于年龄大于 35 岁的辅助生殖患者,以改善他们的生殖结果。此外,我们的研究还表明,PGT-A 对预后不良的患者可能有益处。总之,我们的研究结果表明,PGT-A 是改善高龄女性和有妊娠并发症病史的女性辅助生殖手术生殖效果的重要工具。
{"title":"Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysis.","authors":"Leila Adamyan, Laura Pivazyan, Lilia Obosyan, Ekaterina Krylova, Sapiyat Isaeva","doi":"10.5468/ogs.24028","DOIUrl":"10.5468/ogs.24028","url":null,"abstract":"<p><p>This study aimed to summarize the current knowledge on the benefits of in vitro fertilization/intracytoplasmic sperm injection with preimplantation genetic testing for aneuploidy (PGT-A) and to discuss the role of PGT-A in patients of different ages undergoing assisted reproduction. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 checklist. Registration number: CRD42022354697. Studies were identified by searching the PubMed, Cochrane Library, Google Scholar, Scopus, Embase, and ClinicalTrials databases. Seven meta-analyses were performed with additional stratification of age and prognosis of the women studied. Clinical pregnancy rate per embryo transfer in patients aged >35 years was higher in the PGT-A group (P=0.0002) than in controls. Live birth rate (LBR) per embryo transfer in women 35 years old or younger (P=0.002) was higher in the PGT-A group. The LBR per patient in women aged >35 years was higher in the PGT-A group (P=0.004). The effects of PGT-A on LBR in patients with poor prognosis showed a statistically significant increase (P=0.003). There was no significant difference in the rate between the two groups. PGT-A is effective and can be recommended for patients aged >35 years undergoing assisted reproduction to improve their reproductive outcomes. Moreover, our study showed the possible benefits of PGT-A in patients with a poor prognosis. Overall, our findings suggest that PGT-A is a valuable tool for improving the reproductive outcomes of assisted reproductive procedures in older women and those with a history of pregnancy complications.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"356-379"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prenatal diagnosis and postnatal outcome of fetal intracranial hemorrhage: a single-center experience. 胎儿颅内出血的产前诊断和产后结果:单中心经验。
IF 2 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-07-01 Epub Date: 2024-06-20 DOI: 10.5468/ogs.24097
Suhra Kim, Yun Ji Jung, Jiwon Baik, Hayan Kwon, JoonHo Lee, Ja-Young Kwon, Young-Han Kim

Objective: To assess prenatal ultrasonographic findings and postnatal outcomes in fetuses with intracranial hemorrhage (ICH).

Methods: This retrospective study included fetuses prenatally diagnosed with ICH between December 2012 and August 2023. Maternal characteristics, prenatal ultrasonographic findings, and postnatal outcomes were reviewed.

Results: Twenty-seven fetuses with ICH were reviewed. Intracranial hemorrhage was classified as grade 3 and 4 in 24 fetuses. Twenty-two fetuses had ICH, four had ICH with subdural hemorrhage, and one had ICH with subarachnoid hemorrhage. Ventriculomegaly was the most common ultrasonographic finding, and was observed in 22 of the 27 (81.5%) fetuses. Seven fetuses were lost to follow-up, and four intrauterine fetal deaths occurred. The remaining 16 fetuses were delivered at a median gestational age of 35+2 weeks. The infants were followed-up for 40.1 months (range, 4-88). Nine of the 16 infants underwent ventriculoperitoneal placement. One infant underwent brain surgery for severe epilepsy. Motor impairment, including cerebral palsy, was observed in 13 infants (81.2%). Neurologic impairment occurred in six infants (37.5%), developmental delay in nine (56.2%), and epilepsy in 11 (68.7%).

Conclusion: Fetal ICH is a rare complication diagnosed during pregnancy, which results in subsequent fetal neurological sequelae or death. This study demonstrated that the common ultrasonographic findings in fetal ICH were progressive ventriculomegaly and increased periventricular echogenicity. Fetuses diagnosed with prenatal ICH, especially those affected by higher-grade ICH, may be at an increased risk of long-term neurodevelopmental problems.

目的:评估颅内出血(ICH)胎儿的产前超声检查结果和产后结局:评估颅内出血(ICH)胎儿的产前超声检查结果和产后结局:这项回顾性研究纳入了2012年12月至2023年8月期间产前诊断为ICH的胎儿。研究回顾了母体特征、产前超声检查结果和产后结局:结果:共对 27 例 ICH 胎儿进行了回顾性分析。24 个胎儿的颅内出血分级为 3-4 级。22 名胎儿患有 ICH,4 名胎儿患有 ICH 合并硬膜下出血,1 名胎儿患有 ICH 合并蛛网膜下腔出血。脑室肥大是最常见的超声波检查结果,在 27 个胎儿中有 22 个(81.5%)被观察到。有 7 个胎儿失去了随访机会,4 个胎儿在宫内死亡。其余 16 个胎儿的中位胎龄为 35±2 周。这些婴儿的随访时间为 40.1 个月(4-88 个月)。16 名婴儿中有 9 名接受了脑室腹腔置管手术。一名婴儿因严重癫痫而接受了脑部手术。13名婴儿(81.2%)出现运动障碍,包括脑瘫。6名婴儿(37.5%)出现神经系统损伤,9名婴儿(56.2%)出现发育迟缓,11名婴儿(68.7%)出现癫痫:胎儿 ICH 是一种罕见的孕期并发症,会导致胎儿神经系统后遗症或死亡。这项研究表明,胎儿 ICH 常见的超声波检查结果是进行性脑室肥大和脑室周围回声增强。被诊断为产前 ICH 的胎儿,尤其是高级别 ICH 胎儿,可能会增加出现长期神经发育问题的风险。
{"title":"Prenatal diagnosis and postnatal outcome of fetal intracranial hemorrhage: a single-center experience.","authors":"Suhra Kim, Yun Ji Jung, Jiwon Baik, Hayan Kwon, JoonHo Lee, Ja-Young Kwon, Young-Han Kim","doi":"10.5468/ogs.24097","DOIUrl":"10.5468/ogs.24097","url":null,"abstract":"<p><strong>Objective: </strong>To assess prenatal ultrasonographic findings and postnatal outcomes in fetuses with intracranial hemorrhage (ICH).</p><p><strong>Methods: </strong>This retrospective study included fetuses prenatally diagnosed with ICH between December 2012 and August 2023. Maternal characteristics, prenatal ultrasonographic findings, and postnatal outcomes were reviewed.</p><p><strong>Results: </strong>Twenty-seven fetuses with ICH were reviewed. Intracranial hemorrhage was classified as grade 3 and 4 in 24 fetuses. Twenty-two fetuses had ICH, four had ICH with subdural hemorrhage, and one had ICH with subarachnoid hemorrhage. Ventriculomegaly was the most common ultrasonographic finding, and was observed in 22 of the 27 (81.5%) fetuses. Seven fetuses were lost to follow-up, and four intrauterine fetal deaths occurred. The remaining 16 fetuses were delivered at a median gestational age of 35+2 weeks. The infants were followed-up for 40.1 months (range, 4-88). Nine of the 16 infants underwent ventriculoperitoneal placement. One infant underwent brain surgery for severe epilepsy. Motor impairment, including cerebral palsy, was observed in 13 infants (81.2%). Neurologic impairment occurred in six infants (37.5%), developmental delay in nine (56.2%), and epilepsy in 11 (68.7%).</p><p><strong>Conclusion: </strong>Fetal ICH is a rare complication diagnosed during pregnancy, which results in subsequent fetal neurological sequelae or death. This study demonstrated that the common ultrasonographic findings in fetal ICH were progressive ventriculomegaly and increased periventricular echogenicity. Fetuses diagnosed with prenatal ICH, especially those affected by higher-grade ICH, may be at an increased risk of long-term neurodevelopmental problems.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"393-403"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141427906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Obstetrics and Gynecology Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1